These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8674335)
1. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Vogels MT; van der Meer JW; Goris RJ Crit Care Med; 1996 Jul; 24(7):1196-202. PubMed ID: 8674335 [TBL] [Abstract][Full Text] [Related]
2. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408 [TBL] [Abstract][Full Text] [Related]
3. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376 [TBL] [Abstract][Full Text] [Related]
4. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128 [TBL] [Abstract][Full Text] [Related]
5. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Burdon D; Tiedje T; Pfeffer K; Vollmer E; Zabel P Crit Care Med; 2000 Jun; 28(6):1962-7. PubMed ID: 10890648 [TBL] [Abstract][Full Text] [Related]
6. Increasing cytotoxic activity and production of reactive oxygen and nitrogen intermediates by peritoneal macrophages during the development of multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; Huyben CM; Tax WJ; van der Meer JW; Goris RJ Scand J Immunol; 1996 Oct; 44(4):361-8. PubMed ID: 8845029 [TBL] [Abstract][Full Text] [Related]
7. Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome. Volman TJ; Goris RJ; van der Meer JW; Hendriks T Ann Surg; 2004 Jul; 240(1):142-50. PubMed ID: 15213630 [TBL] [Abstract][Full Text] [Related]
8. Is circulating endotoxin the trigger for the systemic inflammatory response syndrome seen after injury? Kelly JL; O'Sullivan C; O'Riordain M; O'Riordain D; Lyons A; Doherty J; Mannick JA; Rodrick ML Ann Surg; 1997 May; 225(5):530-41; discussion 541-3. PubMed ID: 9193181 [TBL] [Abstract][Full Text] [Related]
9. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. Mazzon E; Esposito E; Di Paola R; Impellizzeri D; Bramanti P; Cuzzocrea S Pharmacol Res; 2011 Jul; 64(1):68-79. PubMed ID: 21193041 [TBL] [Abstract][Full Text] [Related]
10. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Volman TJ; Goris RJ; van der Jagt M; van de Loo FA; Hendriks T Crit Care Med; 2002 Jul; 30(7):1553-9. PubMed ID: 12130978 [TBL] [Abstract][Full Text] [Related]
11. Reprogrammed macrophage tumor necrosis factor and interleukin-1 release with inflammatory pretreatment: differential regulation by endotoxin and zymosan. West MA; Bennet T; Clair L J Trauma; 1995 Sep; 39(3):404-10. PubMed ID: 7473900 [TBL] [Abstract][Full Text] [Related]
12. Peritoneal mesothelial cells produce inflammatory related cytokines. Yao V; Platell C; Hall JC ANZ J Surg; 2004 Nov; 74(11):997-1002. PubMed ID: 15550091 [TBL] [Abstract][Full Text] [Related]
13. Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Verhofstad AA; Lange W; Geeraedts LM; Goris RJ Shock; 1997 Oct; 8(4):261-7. PubMed ID: 9329127 [TBL] [Abstract][Full Text] [Related]
14. Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. Genovese T; Di Paola R; Catalano P; Li JH; Xu W; Massuda E; Caputi AP; Zhang J; Cuzzocrea S Crit Care Med; 2004 Jun; 32(6):1365-74. PubMed ID: 15187521 [TBL] [Abstract][Full Text] [Related]
15. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Malleo G; Mazzon E; Genovese T; Di Paola R; Caminiti R; Esposito E; Bramanti P; Cuzzocrea S Cytokine; 2008 Feb; 41(2):136-43. PubMed ID: 18160304 [TBL] [Abstract][Full Text] [Related]
17. Subchronic effects of perfluorooctanesulfonate exposure on inflammation in adult male C57BL/6 mice. Dong GH; Zhang YH; Zheng L; Liang ZF; Jin YH; He QC Environ Toxicol; 2012 May; 27(5):285-96. PubMed ID: 20737580 [TBL] [Abstract][Full Text] [Related]
18. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shayevitz JR; Miller C; Johnson KJ; Rodriguez JL Shock; 1995 Dec; 4(6):389-96. PubMed ID: 8608394 [TBL] [Abstract][Full Text] [Related]
19. Generation of pro-inflammatory and anti-inflammatory cytokines in the gut in zymosan-induced peritonitis. Sakashita Y; Hiyama E; Imamura Y; Murakami Y; Sugahara Y; Takesue Y; Matsuura Y; Yokoyama T Hiroshima J Med Sci; 2000 Mar; 49(1):43-8. PubMed ID: 10824456 [TBL] [Abstract][Full Text] [Related]
20. Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide. Zhou G; Hu S; Lv Y; Song Q; Zou X; Sheng Z J Trauma; 2011 Jul; 71(1):157-62. PubMed ID: 20805763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]